Evolocumab (Repatha)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses Evolocumab (Repatha)
  • 140 mg/mL, prefilled syringea and autoinjector, subcutaneous injection
  • 120 mg/mL, automated mini-doser with prefilled cartridge, subcutaneous injection.
• Indication: Evolocumab is indicated for the reduction of elevated low-density-lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular disease [ASCVD]):
  • as an adjunct to diet and statin therapy, with or without other lipid-lowering therapies, in patients who require additional lowering of LDL-C
  • as an adjunct to diet, alone or in combination with nonstatin lipid-lowering therapies, in patients for whom a statin is contraindicated